Supernus Pharmaceuticals Inc

+0.15 (+0.54%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.49B
Current PE14.83
Forward PE 23.3
2yr Forward PE 19.69
See more stats
Estimates Current Quarter
Revenue$142.12 Million
Adjusted EPS$0.28
See more estimates
10-Day MA$27.43
50-Day MA$26.49
200-Day MA$28.15
See more pivots

Supernus Pharmaceuticals Inc Stock, NASDAQ:SUPN

9715 Key West Avenue, Rockville, Maryland 20850
United States of America
Phone: +1.301.838.2500
Number of Employees: 563


Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.